Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

video

Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease

Dr. Gill reviews the advantages and challenges of using the newly approved recombinant von WIllebrand factor replacement product in clinical practice.
video

Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

Monotherapy with vadastuximab talirine led to high response rates in older patients with acute myeloid leukemia who are considered unfit for intensive chemotherapy. Dr....
video

Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients

Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results...
video

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

Dr. Schrappe discusses results of the AIEOP-BFM ALL 2000 trial, presented as a plenary abstract at the 2016 ASH Annual Meeting.
video

Ruxolitinib in CMML: Study Shows Promising Results

Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

What Was Hot at ASH 2015?

ASH Clinical News’ Editor-in-Chief Mikkael A. Sekeres, MD, MS, shares his highlights of the 2015 ASH Annual Meeting.
video

Multiple Advances in Multiple Myeloma

Sagar Lonial, MD, reviews the recent advances in the treatment of multiple myeloma, including how to sequence the newly approved myeloma drugs and their...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title